



November 9, 2015

Company Name: HEALIOS K.K.  
Representative: Hardy TS Kagimoto, Representative  
Director and President  
(TSE Mothers Code: 4593)

### **Expansion of the Market for Ophthalmic Surgical Adjuvant**

We are delighted to announce that our ophthalmic surgical adjuvant has been granted marketing approval in Arab Republic of Egypt which marks the seventy-third country/region in which the adjuvant is approved.

Having been granted the exclusive license by Kyushu TLO Company, Limited, we have been developing the ophthalmic surgical adjuvant whose primary component is a dye with high stainability, Brilliant Blue G-250 (“BBG”), discovered by a research team at Kyushu University.

Since September 2010, the adjuvant containing BBG as its primary component has been distributed in Europe by Dutch Ophthalmic Research Center International B.V. (“DORC”), our sub-licensee for territories excluding Japan, and we receive a certain percentage of the sales of the products from DORC as the royalty payment. The high stainability of BBG enables the products to safely stain ILM in the posterior part of the eye in ophthalmic surgery to facilitate ILM peeling and over 120,000 syringes of the products in total were sold last year. Its market is steadily expanding and Arab Republic of Egypt is the seventy-third country/region in which the products have been approved.

Note: The products referred to in this press release have not been approved in Japan. For the latest status of the development progress in relation to the products in Japan and other regions, please see the page entitled “Pipelines” on our website.

Contact address for inquiries regarding this issue:  
Department of Public Relations, HEALIOS K.K.  
Mail: pr@healios.jp